BioMarin Pharmaceutical (NASDAQ: [[ticker:BMRN]]) of Novato, CA plans to buy a biotech manufacturing facility in Ireland that’s owned by New York-based Pfizer (NYSE: [[ticker:PFE]]), according to a press release. BioMarin will purchase the plant for $48.5 million—roughly a fifth of what it would have paid to build a facility like it from scratch. BioMarin will use the plant to make its treatment for Morquio A Syndrome, now in Phase 3 trials, and expects the facility to be licensed by 2015.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
